Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03103893 · ClinicalTrials.gov registry record · Phase 1
Novel Compositions for Treating or Preventing Dermal Disorders
A Phase 1 study of Dermal Atrophy, sponsored by Drexel University.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT03103893 is a Phase 1 study of Dermal Atrophy that has completed, run by Drexel University. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03103893, a Phase 1 study of Dermal Atrophy, has completed, sponsored by Drexel University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial examines the impact of a topical formulation of rapamycin on dermal thickness and senescence.
Conditions Studied
Interventions
- DRUG Rapamycin
Study Locations (1)
Pennsylvania
- Drexel Dermatology - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2017-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03103893
The ClinicalTrials.gov registry entry for NCT03103893 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Drexel University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermal Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Rapamycin is the first listed.
NCT03103893 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03103893 about?
NCT03103893 is a clinical study titled "Novel Compositions for Treating or Preventing Dermal Disorders". This trial examines the impact of a topical formulation of rapamycin on dermal thickness and senescence.
What is the current status of trial NCT03103893?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2017-09-25. Estimated completion is 2017-11-30.
What conditions does trial NCT03103893 study?
This clinical trial studies the following conditions: Dermal Atrophy.
What interventions are being tested in trial NCT03103893?
The interventions under investigation include: Rapamycin (DRUG).
Who is sponsoring clinical trial NCT03103893?
This trial is sponsored by Drexel University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03103893 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.